The FDA has granted fast-track approval to the drug telisotuzumab vedotin (sold as Emrelis) as a first-of-its-kind treatment for certain people who have non-squamous non-small-cell lung cancer.

Zai Lab Limited ( NASDAQ: ZLAB) said on Monday that it received U.S. FDA fast track designation for its antibody-drug ...

The FDA has approved new agents in ovarian cancer and non–small cell lung cancer and paved the way for novel antibody-drug conjugate developments.

Former President Joe Biden was diagnosed with an “aggressive form” of prostate cancer that has spread to his bones, according ...

The U.S. Food and Drug Administration has approved Verastem's combination therapy for patients with a rare type of ovarian ...

The FDA approved retifanlimab (Zynyz; Incyte) as the first and only first-line treatment for advanced anal cancer, supported ...

Incyte Corp.’s Zynyz (retifanlimab-dlwr) has received another U.S. FDA approval and put some distance between it and a 2021 ...

The FDA cleared the first blood test on Friday to help diagnose Alzheimer's disease among older Americans already exhibiting signs and symptoms of the condition.

The U.S. Food and Drug Administration ... non-small cell lung cancer (NSCLC) with high c-Met protein overexpression (OE) who have received a prior systemic therapy. High c-Met protein ...

AbbVie ABBV announced that the FDA has granted accelerated approval to its antibody-drug conjugate (ADC), telisotuzumab vedotin (or Teliso-V), for treating certain patients with non-small cell ...

Emrelis showed a 35% overall response rate and a 7.2-month median duration in high c-Met OE NSCLC patients (n=84). AbbVie and ADARx signed a $335 million upfront siRNA therapy deal, with potential ...